常见肌炎特异性抗体与幼年型皮肌炎临床特征的关系

程苏云, 陆嘉敏, 李丰

中国当代儿科杂志 ›› 2025, Vol. 27 ›› Issue (9) : 1076-1081.

PDF(536 KB)
HTML
PDF(536 KB)
HTML
中国当代儿科杂志 ›› 2025, Vol. 27 ›› Issue (9) : 1076-1081. DOI: 10.7499/j.issn.1008-8830.2502077
论著·临床研究

常见肌炎特异性抗体与幼年型皮肌炎临床特征的关系

作者信息 +

Relationship between common myositis-specific antibodies and clinical features in children with juvenile dermatomyositis

Author information +
文章历史 +

摘要

目的 分析幼年型皮肌炎(juvenile dermatomyositis, JDM)中肌炎特异性抗体(myosositis-specific antibody, MSA)的分布情况,并探讨其与JDM临床特征的关系。 方法 回顾性分析2020年1月—2025年4月收治的72例JDM患儿临床资料,所有患儿均行肌炎抗体检测,分析常见MSA亚型与JDM患儿临床特征的关系。 结果 72例JDM患儿中,MSA阳性45例(62%),其中抗NXP2抗体阳性27例(38%),抗MDA5抗体阳性10例(14%),抗cN1A抗体阳性3例(4%)。抗MDA5抗体阳性患儿发热、关节炎/关节痛、间质性肺病发生率高于MSA阴性患儿(P<0.05)。抗NXP2抗体阳性患儿皮下钙质沉着症、发热、软组织水肿、间质性肺病发生率高于MSA阴性患儿(P<0.05)。抗NXP2抗体阳性患儿的肌酸激酶和肌酸激酶同工酶水平高于抗MDA5抗体阳性和MSA阴性患儿(P<0.017),儿童肌炎评估量表评分低于抗MDA5抗体阳性和MSA阴性患儿(P<0.017)。 结论 JDM患儿MSA阳性率较高,不同MSA亚型与特定临床特征及脏器受累相关,开展MSA检测对疾病诊治具有重要意义。

Abstract

Objective To investigate the distribution of myositis-specific antibodies (MSA) in juvenile dermatomyositis (JDM) and the relationship between MSA and clinical features of JDM. Methods Clinical data of 72 children with JDM hospitalized from January 2020 to April 2025 were reviewed retrospectively, all of whom had been tested for MSA. The relationship between common MSA subtypes and clinical features was analyzed. Results Among the 72 children, 45 (62%) were positive for MSA, including 27 anti-NXP2-positive cases (38%), 10 anti-MDA5-positive cases (14%), and 3 anti-cN1A-positive cases (4%). Compared with the MSA-negative group, the anti-MDA5-positive patients showed significantly higher incidence rates of fever, arthritis, and interstitial lung disease (P<0.05). The anti-NXP2-positive patients exhibited significantly higher incidence rates of calcinosis, fever, soft tissue edema, and interstitial lung disease than the MSA-negative patients (P<0.05). Compared with the anti-MDA5-positive group and MSA-negative group, the anti-NXP2-positive group had significantly higher levels of creatine kinase and creatine kinase isoenzyme (P<0.017) and a significantly lower score of the Childhood Myositis Assessment Scale (P<0.017). Conclusions The positive rate of MSA is high in children with JDM, with different subtypes correlating with specific clinical manifestations and organ involvement. Detection of MSA is crucial for diagnosis and clinical management of JDM.

关键词

幼年型皮肌炎 / 肌炎特异性抗体 / 临床特征 / 儿童

Key words

Juvenile dermatomyositis / Myositis-specific antibody / Clinical feature / Child

引用本文

导出引用
程苏云, 陆嘉敏, 李丰. 常见肌炎特异性抗体与幼年型皮肌炎临床特征的关系[J]. 中国当代儿科杂志. 2025, 27(9): 1076-1081 https://doi.org/10.7499/j.issn.1008-8830.2502077
Su-Yun CHENG, Jia-Min LU, Feng LI. Relationship between common myositis-specific antibodies and clinical features in children with juvenile dermatomyositis[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(9): 1076-1081 https://doi.org/10.7499/j.issn.1008-8830.2502077

参考文献

[1]
Tansley SL, Simou S, Shaddick G, et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort[J]. J Autoimmun, 2017, 84: 55-64. PMCID: PMC5656106. DOI: 10.1016/j.jaut.2017.06.007 .
[2]
李冬梅, 汪利, 刘明月, 等. 幼年皮肌炎临床特征与肌炎抗体相关性分析[J]. 中华儿科杂志, 2020, 58(12): 966-972. DOI: 10.3760/cma.j.cn112140-20200724-00751 .
[3]
管皖珍, 李国民, 李一帆, 等. 幼年型皮肌炎常见肌炎抗体与临床表型的关联分析[J]. 中国循证儿科杂志, 2021, 16(2): 93-98. DOI: 10.3969/j.issn.1673-5501.2021.02.003 .
[4]
Iwata N, Nakaseko H, Kohagura T, et al. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: experience at a single center in Japan[J]. Mod Rheumatol, 2019, 29(5): 802-807. DOI: 10.1080/14397595.2018.1511025 .
[5]
李珊珊, 葛永鹏, 杨阚波, 等. 皮肌炎患者427例肌炎特异性抗体谱及与临床特征相关性分析[J]. 中华风湿病学杂志, 2017, 21(9): 585-594. DOI: 10.3760/cma.j.issn.1007-7480.2017.09.003 .
[6]
Gupta L, Naveen R, Gaur P, et al. Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis[J]. Semin Arthritis Rheum, 2021, 51(1): 113-120. DOI: 10.1016/j.semarthrit.2020.10.014 .
[7]
DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis[J]. J Am Acad Dermatol, 2020, 82(2): 267-281. DOI: 10.1016/j.jaad.2019.06.1309 .
[8]
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7): 344-347. DOI: 10.1056/NEJM197502132920706 .
[9]
Xu Y, Ma X, Zhou Z, et al. Gastrointestinal perforation in anti-NXP2 antibody-associated juvenile dermatomyositis: case reports and a review of the literature[J]. Pediatr Rheumatol Online J, 2021, 19(1): 2. PMCID: PMC7789137. DOI: 10.1186/s12969-020-00486-x .
[10]
Trefond L, Smets P, Beltzung F, et al. Digestive vasculitis: a rare but severe complication of NXP2 dermatomyositis[J]. Rheumatology (Oxford), 2021, 60(5): e165-e166. DOI: 10.1093/rheumatology/keaa740 .
[11]
Pachman LM, Khojah AM. Advances in juvenile dermatomyositis: myositis specific antibodies aid in understanding disease heterogeneity[J]. J Pediatr, 2018, 195: 16-27. PMCID: PMC5881602. DOI: 10.1016/j.jpeds.2017.12.053 .
[12]
Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes[J]. J Intern Med, 2016, 280(1): 24-38. PMCID: PMC4914449. DOI: 10.1111/joim.12444 .
[13]
Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset[J]. Rheumatology (Oxford), 2014, 53(12): 2204-2208. PMCID: PMC4241891. DOI: 10.1093/rheumatology/keu259 .
[14]
Aouizerate J, De Antonio M, Bader-Meunier B, et al. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis[J]. Rheumatology (Oxford), 2018, 57(5): 873-879. DOI: 10.1093/rheumatology/kex516 .
[15]
Sharma A, Gupta A, Rawat A, et al. Long-term outcome in children with juvenile dermatomyositis: a single-center study from north India[J]. Int J Rheum Dis, 2020, 23(3): 392-396. DOI: 10.1111/1756-185X.13759 .
[16]
Wang A, Morgan GA, Paller AS, et al. Skin disease is more recalcitrant than muscle disease: a long-term prospective study of 184 children with juvenile dermatomyositis[J]. J Am Acad Dermatol, 2021, 84(6): 1610-1618. DOI: 10.1016/j.jaad.2020.12.032 .
[17]
Fredi M, Bartoli F, Cavazzana I, et al. Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options[J]. Clin Exp Rheumatol, 2017, 35(2): 303-308.
[18]
Sag E, Demir S, Bilginer Y, et al. Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis[J]. Semin Arthritis Rheum, 2021, 51(1): 95-100. DOI: 10.1016/j.semarthrit.2020.10.007 .
[19]
Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies[J]. Front Immunol, 2021, 12: 773352. PMCID: PMC8564476. DOI: 10.3389/fimmu.2021.773352 .
[20]
Matsushita T, Mizumaki K, Kano M, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis[J]. Br J Dermatol, 2017, 176(2): 395-402. DOI: 10.1111/bjd.14882 .
[21]
Xu YT, Zhang YM, Yang HX, et al. Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease[J]. Rheumatology (Oxford), 2022, 62(1): 397-406. DOI: 10.1093/rheumatology/keac229 .
[22]
Fujisawa T. Management of myositis-associated interstitial lung disease[J]. Medicina (Kaunas), 2021, 57(4): 347. PMCID: PMC8065549. DOI: 10.3390/medicina57040347 .
[23]
Mamyrova G, Kishi T, Shi M, et al. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America[J]. Rheumatology (Oxford), 2021, 60(4): 1839-1849.PMCID: PMC8023991. DOI: 10.1093/rheumatology/keaa429 .
[24]
Ueki M, Kobayashi I, Takezaki S, et al. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies[J]. Mod Rheumatol, 2019, 29(2): 351-356. DOI: 10.1080/14397595.2018.1452353 .
[25]
Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis[J]. Arthritis Care Res (Hoboken), 2013, 65(8): 1316-1324. DOI: 10.1002/acr.21985 .
[26]
Lu X, Peng Q, Wang G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress[J]. Nat Rev Rheumatol, 2024, 20(1): 48-62. DOI: 10.1038/s41584-023-01054-9
[27]
Zhong L, Yu Z, Song H. Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: a meta-analysis of 20 cohorts[J]. Clin Immunol, 2019, 198: 11-18. DOI: 10.1016/j.clim.2018.11.008.28
[28]
Li L, Liu C, Cheng L, et al. Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis[J]. Clin Rheumatol, 2021, 40(3): 819-832. DOI: 10.1007/s10067-020-05291-1 .
[29]
Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies[J]. Medicine (Baltimore), 2013, 92(4): 223-243. PMCID: PMC3721421. DOI: 10.1097/MD.0b013e31829d08f9 .
[30]
Bermudez J, Heim X, Bertin D, et al. Lung involvement associated with anti-NXP2 autoantibodies in inflammatory myopathies: a French monocenter series[J]. Expert Rev Respir Med, 2020, 14(8): 845-850. DOI: 10.1080/17476348.2020.1767598 .
[31]
Wang X, Ding Y, Zhou Z, et al. Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children[J]. Pediatr Rheumatol Online J, 2021,19(1): 6. PMCID: PMC7788734. DOI: 10.1186/s12969-020-00492-z .

脚注

所有作者声明无利益冲突。

基金

广州市科技计划项目(2023A03J0902)
广州市卫健委一般引导项目(20241A011027)

编委: 王颖

版权

版权所有 © 2023中国当代儿科杂志
PDF(536 KB)
HTML

Accesses

Citation

Detail

段落导航
相关文章

/